Cargando…
COVID-19 in a patient receiving adjuvant breast cancer chemotherapy with granulocyte olony-stimulating factor (G-CSF) support: A case report
Patients receiving chemotherapy are at high risk for severe infections and complications such as acute respiratory syndrome. The most commonly used adjuvant chemotherapy protocols (docetaxel-cyclophosphamide every 3 weeks or the dose-dense regimen, doxorubicin-cyclophosphamide every 2 weeks followed...
Autores principales: | Yerushalmi, Rinat, Sagi, Moshe, Goldvaser, Hadar, Daliot, Jonathan, Mutai, Raz, Krause, Ilan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060854/ https://www.ncbi.nlm.nih.gov/pubmed/33903823 http://dx.doi.org/10.3892/mco.2021.2279 |
Ejemplares similares
-
Adjuvant Docetaxel and Cyclophosphamide (DC) with Prophylactic Granulocyte Colony-Stimulating Factor (G-CSF) on Days 8 &12 in Breast Cancer Patients: A Retrospective Analysis
por: Yerushalmi, Rinat, et al.
Publicado: (2014) -
Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
por: Reinhorn, Daniel, et al.
Publicado: (2021) -
The impact of endogenous estrogen exposures on the characteristics and outcomes of estrogen receptor positive, early breast cancer
por: Korzets, Yasmin, et al.
Publicado: (2021) -
Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer
por: Mutai, Raz, et al.
Publicado: (2021) -
Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis
por: Goldvaser, Hadar, et al.
Publicado: (2019)